CoolSculpting Elite: Next-Generation Fat Reduction System Launches

January 26, 2021

CoolSculpting Elite, its next-generation fat reduction system with applicators designed to complement the body’s natural curves. Allergan Aesthetics, an AbbVie company announced the news today.

CoolSculpting Elite harnesses proven CoolSculpting® technology to target, freeze, and eliminate treated fat cells. CoolSculpting Elite is FDA cleared to treat visible fat bulges in nine areas of the body including the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), upper arm, and the submental and submandibular areas.

“The number one aesthetic concern for consumers is excess body fat1. CoolSculpting® has been an industry-leader, creating the market for non-invasive fat reduction over 10 years ago. Now CoolSculpting® Elite builds on that heritage with a completely re-invented next-generation technology that delivers results,” says Carrie Strom, Senior Vice President, AbbVie, and President, Global Allergan Aesthetics. “We understand the challenges of today’s world and as people prepare to go from being online to spending more time in person, CoolSculpting® Elite can help them address their bothersome fat.”

CoolSculpting Elite will launch with a new applicator collection, which includes seven different shapes and sizes. The innovative new C-shaped applicators are designed to complement the body’s natural curves for improved fit and comfort during initial tissue draw and features up to an 18% larger cooling area as compared to the previous generation CoolSculpting applicators. The clinical significance of these data has not been established.

“CoolSculpting® is a critical part of my business and a device I’ve relied on to help my patients achieve their desired outcome of reducing stubborn fat.” said Dr. Sabrina Fabi, Board Certified Dermatologist and Associate Research Director at Cosmetic Laser Surgery in San Diego. “The dual applicators allow us to treat two areas at the same time, safely freezing twice the fat compared to using a single CoolSculpting applicator, which helps us save on time. With the Elite applicator collection we are able to treat a wide range of body areas and personalize each patient’s treatment plan.”

Allergan Aesthetics™ is now taking orders for the CoolSculpting® Elite device, and the first units will ship in Q1 2021.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”